Comparing two blood sugar targets during labor in pregnant people with diabetes
Tests looser versus tighter blood sugar control during labor in pregnant adults with diabetes.
Plain-language title generated from the registry record
Registry title: Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM)
Key facts
- Where
- Columbus, United StatesSee the site
- Phase
- Phase 4
Where in United States
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal MedicineColumbus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University
- Trial code
- NCT07293715
- Record updated
- 9 November 2026
- Original description
PRISM is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with pregestational diabetes using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.Read full original descriptionShow less
Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM)
PRISM is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with pregestational diabetes using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.
Inclusion: Pregnant individuals; ≥ 18 years old; Type 1 and Type 2 diabetes; Intention for vaginal delivery and admitted to Labor and Delivery; Singleton, non-anomalous fetus; Gestational age greater than or equal to 35 weeks gestation; Cervical dilation is less than 6 cm; Delivering at the study institution.
Exclusion: Receipt of antenatal corticosteroids within 7 days of randomization; Scheduled cesarean delivery; Cervical dilation ≥ 6 cm on presentation to L\&D; Fetal demise; Major fetal anomaly (attached); Multiple gestation; Non-English speaking.